Buy was Reconfirmed on GW Pharmaceuticals (NASDAQ:GWPH) by Bank of America; with $200 Target.

June 27, 2018 - By Mary Anderson

Reiterated GW Pharmaceuticals (NASDAQ:GWPH) Rating.

Bank of America have a $200 target price per share on GW Pharmaceuticals (NASDAQ:GWPH) shares. On Tuesday, 26 June the $3.93B MC company have Buy stock rating. This target price per share gives a potential 43.53 % upside on the stock.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

In total 5 analysts cover GW Pharma (NASDAQ:GWPH). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:GWPH)’s analyst reports since December 28, 2017 according to StockzIntelligence Inc. On Wednesday, April 18 Cowen & Co maintained GW Pharmaceuticals plc (NASDAQ:GWPH) with “Buy” rating. On Tuesday, April 17 the rating was maintained by Cantor Fitzgerald with “Buy”. The stock rating was maintained by Leerink Swann with “Buy” on Thursday, December 28. On Tuesday, January 23 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Leerink Swann. The company rating was maintained by Cantor Fitzgerald on Monday, February 5. On Tuesday, June 26 the firm has “Buy” rating by Bank of America given. On Tuesday, February 6 the rating was maintained by Bank of America with “Buy”. The company rating was maintained by Cantor Fitzgerald on Monday, June 25. On Tuesday, June 26 the firm has “Buy” rating by Goldman Sachs given. On Tuesday, February 6 the stock has “Outperform” rating by Leerink Swann.

The stock decreased 4.89% or $7.17 during the last trading session, hitting $139.34.GW Pharmaceuticals plc has 682,486 shares volume, 54.71% up from normal. GWPH is uptrending and has moved 49.14% since June 27, 2017. GWPH outperformed by 36.57% the S&P 500.

Investors expect GW Pharmaceuticals plc (NASDAQ:GWPH)’s quarterly earnings on August, 6., according to Faxor. Analysts expect change of 15.46 % or $0.32 from previous year’s $-2.07 earnings per share compared to current’s $-2.39 earnings per share. After $-3.12 EPS report last quarter, Wall Street now sees -23.40 % EPS growth of GW Pharmaceuticals plc.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The firm is worth $3.93 billion. The firm operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Currently it has negative earnings. The Company’s lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

For more GW Pharmaceuticals plc (NASDAQ:GWPH) news published recently go to: Bloomberg.com, Seekingalpha.com, Benzinga.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Yuan Devaluation Unlikely, Don’t Hit Panic Button: BBH’s Thin” published on June 27, 2018, “D-Day Approaches For GW Pharma” on June 20, 2018, “GW Pharma’s Epidiolex Becomes First Cannabis-Based FDA-Approved Drug” with a publish date: June 25, 2018, “Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher …” and the last “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” with publication date: June 26, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: